Iovance Biotherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Iovance Biotherapeutics generated cash of -$361,820,000, which is less than the previous year. Cash used in financing activities reached the amount of $462,959,000 last year. Net change in cash is therefore -$56,843,000.
Cash Flow
| 2014 | -8.63M | -1.59M | 35.46M |
|---|---|---|---|
| 2015 | -18.38M | -91.15M | 78.26M |
| 2016 | -32.66M | 8.89M | 96.90M |
| 2017 | -78.70M | 58.67M | 58.68M |
| 2018 | -101.24M | -386.27M | 424.30M |
| 2019 | -158.88M | 90.02M | 6.13M |
| 2020 | -205.13M | -317.85M | 576.42M |
| 2021 | -227.94M | 132K | 239.26M |
| 2022 | -292.75M | 256.45M | 190.15M |
| 2023 | -361.82M | -155.24M | 462.95M |
IOVA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 238.16M | 84.31M | 72.85M | 19.41M | 82.15M | 145.37M | 106.71M | 33.58M | 44.90M | 19.67M |
Operating activities | ||||||||||
Net income | -444.03M | -395.89M | -342.25M | -259.58M | -197.55M | -123.58M | -92.06M | -52.89M | -27.66M | -12.03M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 33.12M | 21.13M | 13.98M | 1.14M | 1.16M | 956K | 952K | 978K | 999K | 88.22K |
Stock-based compensation expense | 62.62M | 84.02M | 69.76M | 40.88M | 24.27M | 0 | 11.96M | 18.90M | 8.52M | 3.81M |
| Deferred income tax benefit | 62.62M | 84.02M | 69.76M | 40.88M | 24.27M | 0 | 11.96M | 18.90M | 8.52M | 3.81M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -149K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -10.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 4.82M | 5.88M | 6.97M | -2.96M | 12.70M | 1.50M | 369K | -250K | -32K | -354.94K |
Cash generated by operating activities | -361.82M | -292.75M | -227.94M | -205.13M | -158.88M | -101.24M | -78.70M | -32.66M | -18.38M | -8.63M |
Investing activities | ||||||||||
Purchases Of Investments | -205.90M | -245.81M | -725.20M | -947.66M | -417.65M | -426.08M | 0 | -110.24M | -160.61M | 0 |
Investments In Property Plant And Equipment | -22.29M | -20.42M | -37.57M | -46.79M | -6.91M | -1.19M | -1.02M | -1.52M | -1.14M | -1.59M |
Acquisitions Net | -212.63M | -276.87M | -37.70M | 271.06M | -96.94M | 0 | 0 | 0 | 19.94M | 0 |
Cash generated by investing activities | -155.24M | 256.45M | 132K | -317.85M | 90.02M | -386.27M | 58.67M | 8.89M | -91.15M | -1.59M |
Financing activities | ||||||||||
Common Stock Issued | 463.28M | 189.50M | 238.26M | 576.42M | 6.13M | 0 | 53.66M | 95.68M | 68.30M | 32.24M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -284K | -312K | -223K | -1.25M | -642K | 0 | 0 |
Repayments of term debt | 0 | 0 | -1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 462.95M | 190.15M | 239.26M | 576.42M | 6.13M | 424.30M | 58.68M | 96.90M | 78.26M | 35.46M |
Net Change In Cash | -56.84M | 153.84M | 11.45M | 53.43M | -62.73M | -63.22M | 38.65M | 73.13M | -31.26M | 25.23M |
Cash at end of period | 181.31M | 238.16M | 84.31M | 72.85M | 19.41M | 82.15M | 145.37M | 106.71M | 13.64M | 44.90M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |